KeyBanc lowered the firm’s price target on Progyny to $45 from $50 and keeps an Overweight rating on the shares after another record result and selling season marked by an anticipated 1.3M lives to be added next year. The firm maintains that the company is well-positioned to offset any potential headwinds from client layoffs with new client wins driven by secular and company-specific demand trends; high retention and expansion of services given its outcomes and cost savings; and ongoing healthy utilization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PGNY:
- Progyny sees FY23 revenue $1.087B-$1.1B, consensus 1.08B
- Progyny reports Q3 EPS 16c, consensus 12c
- Progyny, Inc. Announces Third Quarter 2023 Results
- ‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks
- The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families